ES2548295T3 - Sistema terapéutico transdérmico con componentes de urea - Google Patents

Sistema terapéutico transdérmico con componentes de urea Download PDF

Info

Publication number
ES2548295T3
ES2548295T3 ES08871775.6T ES08871775T ES2548295T3 ES 2548295 T3 ES2548295 T3 ES 2548295T3 ES 08871775 T ES08871775 T ES 08871775T ES 2548295 T3 ES2548295 T3 ES 2548295T3
Authority
ES
Spain
Prior art keywords
layer
urea
therapeutic system
transdermal therapeutic
urea components
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08871775.6T
Other languages
English (en)
Inventor
Michael Horstmann
Gerd Hoffmann
Sandra Wiedersberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Application granted granted Critical
Publication of ES2548295T3 publication Critical patent/ES2548295T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Sistema terapéutico transdérmico (TTS) para la entrega de unas sustancias activas farmacéuticas a través de la piel, que contiene una capa dorsal (R) que es impermeable para la sustancia activa, y por lo menos una capa (S) que contiene una sustancia activa, en el que la capa (H) que está orientada hacia la piel, contiene una urea sólida, siendo la proporción ponderal de la urea con respecto al material de base de la capa (H) de por lo menos 20 % (m/m) y presentándose la urea, que está contenida en ella, en por lo menos un 50 % en peso en un tamaño de granos de más que 50 μm.

Description

imagen1
imagen2
imagen3
imagen4

Claims (1)

  1. imagen1
ES08871775.6T 2008-01-30 2008-12-09 Sistema terapéutico transdérmico con componentes de urea Active ES2548295T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008006791 2008-01-30
DE102008006791A DE102008006791B4 (de) 2008-01-30 2008-01-30 Transdermales Therapeutisches System mit Harnstoff-Komponente und Verfahren zu dessen Herstellung
PCT/EP2008/010426 WO2009095057A2 (de) 2008-01-30 2008-12-09 Transdermales therapeutisches system mit harnstoff-komponente

Publications (1)

Publication Number Publication Date
ES2548295T3 true ES2548295T3 (es) 2015-10-15

Family

ID=40386379

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08871775.6T Active ES2548295T3 (es) 2008-01-30 2008-12-09 Sistema terapéutico transdérmico con componentes de urea

Country Status (14)

Country Link
US (1) US9066887B2 (es)
EP (1) EP2234605B1 (es)
JP (1) JP5389824B2 (es)
KR (1) KR20100105866A (es)
CN (1) CN101909607B (es)
AU (1) AU2008349007B2 (es)
BR (1) BRPI0821975B8 (es)
CA (1) CA2710640C (es)
DE (1) DE102008006791B4 (es)
ES (1) ES2548295T3 (es)
MX (1) MX2010008334A (es)
PL (1) PL2234605T3 (es)
WO (1) WO2009095057A2 (es)
ZA (1) ZA201004012B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106333939A (zh) * 2016-10-09 2017-01-18 常州亚环环保科技有限公司 一种药用透皮材料的制备方法
CN109549929A (zh) * 2017-09-27 2019-04-02 天津金耀集团有限公司 一种有机固体溶液降低皮质激素药物粒径的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1404583A (en) * 1971-10-08 1975-09-03 Vymatt Sa Urea compositions and methods of preparation thereof
CS164542B1 (es) * 1973-02-15 1975-11-07
EP0006724B1 (en) * 1978-06-16 1982-12-01 Phares Pharmaceutical Research N.V. Pharmaceutical compositions containing urea
US4687481A (en) * 1984-10-01 1987-08-18 Biotek, Inc. Transdermal drug delivery system
US4699777A (en) * 1985-08-21 1987-10-13 Schering Corporation Compositions and method for enhancement of the transdermal flux of albuterol with a combination of 1-dodecyl-azacyclopheptan-2-one and urea
US5230896A (en) * 1989-10-12 1993-07-27 Warner-Lambert Company Transdermal nicotine delivery system
DE4210165A1 (de) * 1991-07-30 1993-02-04 Schering Ag Transdermale therapeutische systeme
DE4310012A1 (de) * 1993-03-27 1994-09-29 Roehm Gmbh Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung
WO1997039740A1 (en) * 1996-04-22 1997-10-30 Toyama Chemical Co., Ltd. Patch containing 1,2-ethanediol derivatives or salts thereof
DE19701949A1 (de) 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
FR2761889B1 (fr) * 1997-04-11 1999-12-31 Oreal Patch pharmaceutique, cosmetique ou dermo-pharmaceutique pour la delivrance de plusieurs composes actifs de nature differente
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
GB9826656D0 (en) * 1998-12-03 1999-01-27 Novartis Ag Organic compounds
NZ524940A (en) * 2000-11-06 2003-08-29 Samyang Corp A multilayered sandwich transdermal drug delivery system with improved water absorbability and adhesion properties
DK1341515T3 (da) * 2000-12-15 2007-01-29 Intendis Gmbh Vandfri hudplejeformuleringer, der omfatter mikroniseret urinstof, og fremgangsmåde til fremstilling af samme
US20050020658A1 (en) * 2002-11-21 2005-01-27 Katsuyuki Inoo Selective cyclooxygenase-2 inhibitor patch
FR2867978B1 (fr) * 2004-03-29 2009-02-20 Galderma Res & Dev Patch d'amorolfine pour le traitement de l'onychomicose
DE102004028284A1 (de) 2004-06-11 2006-01-05 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System auf Basis eines Schmelzklebstoffs zur Anwendung von Norelgestromin

Also Published As

Publication number Publication date
ZA201004012B (en) 2011-02-23
AU2008349007B2 (en) 2014-10-02
HK1151716A1 (en) 2012-02-10
CA2710640A1 (en) 2009-08-06
MX2010008334A (es) 2010-08-23
EP2234605B1 (de) 2015-08-05
BRPI0821975B8 (pt) 2023-02-07
US20100310634A1 (en) 2010-12-09
BRPI0821975A2 (pt) 2015-06-23
US9066887B2 (en) 2015-06-30
CN101909607A (zh) 2010-12-08
AU2008349007A1 (en) 2009-08-06
EP2234605A2 (de) 2010-10-06
PL2234605T3 (pl) 2016-01-29
JP5389824B2 (ja) 2014-01-15
JP2011510936A (ja) 2011-04-07
CN101909607B (zh) 2014-05-14
DE102008006791B4 (de) 2011-11-24
KR20100105866A (ko) 2010-09-30
WO2009095057A2 (de) 2009-08-06
WO2009095057A3 (de) 2010-03-04
CA2710640C (en) 2015-12-08
DE102008006791A1 (de) 2009-08-06
BRPI0821975B1 (pt) 2019-10-08

Similar Documents

Publication Publication Date Title
ES2581985T3 (es) Sistema terapéutico transdérmico que contiene norelgestromina para la contracepción y el reemplazo hormonal
ES2543977T3 (es) Sistema terapéutico transdérmico para la administración del principio activo buprenorfina
Segovia-Mendoza et al. Combinations of calcitriol with anticancer treatments for breast cancer: an update
CL2007003726A1 (es) Anticuerpos anti-receptor del factor del crecimiento similar a la insulina i (igf-ir); composicion farmaceutica que lo contiene; y su uso para tratar el cancer.
CL2011000935A1 (es) Composicion farmaceutica que comprende acetaminofeno y un material de tramadol complejo, que exhibe una liberacion sostenida y coordinada a traves de una capa de liberacion sostenida y otra de liberacion inmediata; metodo de preparacion;y el uso de un material complejo de tramadol y acetaminofeno para preparar un medicamento para el tratamiento del dolor.
ES2527300T3 (es) Método para emitir un material volátil desde un difusor
CL2007003000A1 (es) Compuestos derivados de biaril eter urea; composicion farmaceutica que los contienen; y su uso para el tratamiento de enfermedades o afecciones asociadas a la actividad de amida hidrolasa de acidos grasos (faah).
CL2013002414A1 (es) Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension.
CL2008000133A1 (es) Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e
BR112012027651A2 (pt) método, e, sistema
AR077638A1 (es) Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
ES2646737T3 (es) Sistema terapéutico transdérmico para clorhidrato de ácido 5-aminolevulínico
BR112013030592A2 (pt) estrutura absorvente para artigos absorventes
CL2012001321A1 (es) Compuestos derivados de espiro inden (o indan) - 1,4-piperidin o espiro indolin - 3,4-piperidin, activadores gpr40; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes.
UY31406A1 (es) "producto de dispersion solida que contiene un compuesto a base de n-aril urea".
ES2557988T3 (es) Método para tratar enfermedades de próstata basado en el suministro local de principios activos
CR7952A (es) Sistema terapeutico transdermico estable a los rayos uv
CL2008003024A1 (es) Compuestos derivados de alquilsulfonilbenzotiazol, moduladores del receptor de grelina; formulacion farmaceutica; y uso para el tratamiento de obesidad o sobrepeso, diabetes, sindrome metabolico, entre otras.
ES2548295T3 (es) Sistema terapéutico transdérmico con componentes de urea
ECSP14010605A (es) Sistema para la administración de fármacos
AR033861A1 (es) Sistema terapeutico transcutaneo con testosterona y procedimiento para su fabricacion
ECSP088408A (es) Composiciones farmacéuticas que comprenden combinaciones de analgésicos y anticonvulsivantes para el tratamiento del dolor agudo y crónico
BR0313092A (pt) Sistema de liberação transdérmica aperfeiçoado
BR112012014107A2 (pt) sistema terapêutico transdérmico para administração de peptídeos